Form 4: Centessa Pharma Exec Exercises Options, Sells Shares

Centessa Pharmaceuticals' President of Orexin Program, Mario Alberto Accardi, exercised stock options and subsequently sold a portion of his ordinary shares under a pre-arranged trading plan.

Summary

• Mario Alberto Accardi, President of the Orexin Program at Centessa Pharmaceuticals plc, engaged in two transactions on December 8, 2025.
• Accardi exercised 5,000 share options at an exercise price of $9.53 per share, acquiring 5,000 Ordinary Shares.
• Following the option exercise, Accardi disposed of 10,000 Ordinary Shares at a price of $30 per share.
• The sale of 10,000 shares was executed pursuant to a Rule 10b5-1 trading plan adopted on February 14, 2025.
• After these transactions, Accardi's direct beneficial ownership of Ordinary Shares stands at 188,801.
• Accardi retains 6,250 derivative securities (share options) following the reported transactions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns about its timing or motivation. The executive also realized a significant profit from the option exercise.

Positives

• The executive exercised options at $9.53 and sold shares at $30, indicating a profitable transaction for the insider.
• The sale was conducted under a Rule 10b5-1 trading plan, which suggests a pre-scheduled liquidity event rather than a reaction to immediate, non-public information.

Negatives

• The net effect of the transactions is a reduction in the reporting person's direct beneficial ownership of Ordinary Shares by 5,000 shares (10,000 sold 5,000 acquired from exercise).

Future Outlook

na

Industry Context

This filing represents a routine insider transaction, common in the biotechnology and pharmaceutical industry where executive compensation often includes stock options. Such transactions are typically part of an executive's long-term financial planning and liquidity management.

Stakeholder Impact

• Shareholders: May view the insider sale with mixed feelings; some may see it as a normal part of executive compensation and financial planning, especially given the 10b5-1 plan, while others might interpret any insider selling as a slight negative signal, despite the pre-planned nature.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The insider transaction, while involving a sale, was conducted under a pre-arranged 10b5-1 plan, which reduces its immediate signaling power regarding the company's short-term prospects. The executive also realized a substantial profit from the option exercise. This event alone does not provide sufficient new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Centessa Pharmaceuticals, CNTA, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation